Package 0904-6583-04

{"route": ["ORAL"], "spl_id": "6ce78aad-72e7-44df-99c3-f6b91098f7e5", "openfda": {"nui": ["N0000175656", "N0000175462", "N0000009947"], "unii": ["2T8Q726O95"], "rxcui": ["199147"], "spl_set_id": ["6fd4d6b9-65ea-4988-8d6f-dd220ec5052d"], "pharm_class_epc": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["Major Pharmaceuticals"]}, "finished": true, "packaging": [{"sample": false, "description": "30 BLISTER PACK in 1 CARTON (0904-6583-04)  / 1 TABLET, FILM COATED in 1 BLISTER PACK", "package_ndc": "0904-6583-04", "marketing_start_date": "20111202"}], "brand_name": "LAMIVUDINE", "product_id": "0904-6583_6ce78aad-72e7-44df-99c3-f6b91098f7e5", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "product_ndc": "0904-6583", "generic_name": "lamivudine", "labeler_name": "Major Pharmaceuticals", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "LAMIVUDINE", "active_ingredients": [{"name": "LAMIVUDINE", "strength": "150 mg/1"}], "application_number": "ANDA091606", "marketing_category": "ANDA", "marketing_start_date": "20111202", "listing_expiration_date": "20261231"}